These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)]. Namba S; Ishimitsu H; Nakasone S No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908 [No Abstract] [Full Text] [Related]
4. [Therapy of parkinsonism using L-Dopa (Brocadopa)]. Jörg J Med Welt; 1975 Jan; 26(3):124-6. PubMed ID: 1110622 [No Abstract] [Full Text] [Related]
5. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)]. García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591 [No Abstract] [Full Text] [Related]
6. [Long-term results of L-dopa treatment of parkinsonism]. Barbeau A Union Med Can; 1975 Jan; 104(1):32-8. PubMed ID: 1111195 [No Abstract] [Full Text] [Related]
7. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)]. Ulm G Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619 [No Abstract] [Full Text] [Related]
9. Treatment of parkinsonism by dopaflex (L-DOPA). Grbesa B; Velicković A Ther Hung; 1977; 25(3):106-8. PubMed ID: 929475 [No Abstract] [Full Text] [Related]
10. [Risks of modern therapy for parkinsonism, and their consequences (author's transl)]. Jörg J; Kleine D Nervenarzt; 1979 Jan; 50(1):33-42. PubMed ID: 424033 [No Abstract] [Full Text] [Related]
11. [Absorption, excretion, and clinical effects of L-dopa preparation with superenteric coating in parkinsonism (author's transl)]. Tohgi H; Ogawa M No To Shinkei; 1977 Aug; 29(8):873-8. PubMed ID: 907761 [No Abstract] [Full Text] [Related]
12. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)]. Puca FM; Megna GF; Masi G; Specchio LM Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268 [No Abstract] [Full Text] [Related]
13. [Early or late onset of L-dopa treatment in Parkinson disease?]. von Kummer R; Schneevoigt K Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131 [No Abstract] [Full Text] [Related]
14. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)]. Campanella G; Pennetta R Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267 [No Abstract] [Full Text] [Related]
15. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism]. Neĭmark EZ; Evtushenko SK; Dukhovnaia MA Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979 [TBL] [Abstract][Full Text] [Related]
16. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)]. Eisenlohr JJ; Gehlen W MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699 [No Abstract] [Full Text] [Related]
17. [Experiences in the treatment of Parkinsonism using a combination of L-dopa and alpha-methyldopa-hydrazine]. Vymazal J; Roth B; Nevsímal O Cesk Neurol Neurochir; 1976 Mar; 39(2):59-62. PubMed ID: 1260921 [No Abstract] [Full Text] [Related]
18. [Combined treatment of parkinsonism with L-dopa and Parkopan]. Lukasiewicz K Wiad Lek; 1977 May; 30(10):775-7. PubMed ID: 867994 [No Abstract] [Full Text] [Related]
19. [Use of the preparation L-dopa in parkinsonism]. Proniv DI; Sirotina OS; Bukhovtsev PP; Mis'kiv IaI Vrach Delo; 1976 Jan; (1):113-6. PubMed ID: 1246837 [No Abstract] [Full Text] [Related]
20. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)]. Agid Y; Quinn N; Lhermitte F Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]